Proteomic Analysis for the Diagnosis of Fibrinogen Aα-Chain Amyloidosis by Taylor, GW et al.
CLINICAL RESEARCHCorre
Centr
Colleg
E-mai
Recei
April
KidneyProteomic Analysis for the Diagnosis
of Fibrinogen Aa-Chain Amyloidosis
Graham W. Taylor1, Janet A. Gilbertson1, Rabya Sayed1,2, Angel Blanco1, Nigel B. Rendell1,
Dorota Rowczenio1, Tamer Rezk1,2, P. Patrizia Mangione1, Diana Canetti1, Paul Bass2,
Philip N. Hawkins1 and Julian D. Gillmore1,2
1National Amyloidosis Centre and Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University
College London, London, UK; and 2Centre for Nephrology, Division of Medicine, Royal Free Campus, University College
London, London, UKIntroduction: Hereditary ﬁbrinogen Aa-chain (AFib) amyloidosis is a relatively uncommon renal disease
associated with a small number of pathogenic ﬁbrinogen Aa (FibA) variants; wild-type FibA normally does
not result in amyloid deposition. Proteomics is now routinely used to identify the amyloid type in clinical
samples, and we report here our algorithm for identiﬁcation of FibA in amyloid.
Methods: Proteomics data from 1001 Congo red–positive patient samples were examined using the
Mascot search engine to interrogate the Swiss-Prot database and generate protein identity scores. An
algorithm was applied to identify FibA as the amyloid protein based on Mascot scores. FibA variants were
identiﬁed by appending the known amyloidogenic variant sequences to the Swiss-Prot database.
Results: AFib amyloid was identiﬁed by proteomics in 64 renal samples based on the Mascot scores
relative to other amyloid proteins, the presence of a pathogenic variant, and coverage of the p.449-621
sequence. Contamination by blood could be excluded from a comparison of the FibA score with that of
the ﬁbrinogen b and g chains. The proteomics results were consistent with the clinical diagnosis. Four
additional renal samples did not fulﬁll all the criteria using the algorithm but were adjudged as AFib
amyloid based on a full assessment of the clinical and biochemical results.
Conclusion: AFib amyloid can be identiﬁed reliably in glomerular amyloid by proteomics using a score-
based algorithm. Proteomics data should be used as a guide to AFib diagnosis, with the results consid-
ered together with all available clinical and laboratory information.
Kidney Int Rep (2019) -, -–-; https://doi.org/10.1016/j.ekir.2019.04.007
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).A myloid, an extracellular accumulation of mis-folded, ﬁbrillary insoluble protein, is diagnosed
on the basis of its pathognomonic histologic appear-
ance, notably apple-green birefringence when stained
with Congo red and viewed under crossed polarized
light.1,2 More than 30 different proteins can generate am-
yloid ﬁbrils in vivo, and these individual proteins form
the basis of the classiﬁcation of amyloidosis. The natural
history, prognosis, and management of amyloidosis is
dependent on the precursor protein from which the am-
yloid ﬁbrils are derived (i.e., the amyloid type), which
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International Reports (2019) -, -–-presenting with the disease. Renal amyloid usually man-
ifests with proteinuria and/or chronic kidney disease and
is the cause of approximately 1% of end-stage kidney
disease in the Western world.3 Amyloid deposits in the
kidney may arise from immunoglobulin light chains, am-
yloid A, FibA,4 apolipoproteins A-I, A-II, A-IV, C2, and
C3,5–9 lysozyme,10 transthyretin,11 and leukocyte chemo-
tactic factor 2.12 AFib amyloidosis accounts for <5% of
the patients with renal amyloidosis attending our clinic.
Autosomal-dominant AFib amyloidosis, ﬁrst identiﬁed in
1993 in a Peruvian family,4 is the most common form of
hereditary renal amyloidosis in the United Kingdom and
Europe13,14 and is associated with more than 14 different
mutations of the ﬁbrinogen A a-chain gene (FGA), which
is located on chromosome 4 and has 6 exons.13,15 These
mutations are either single nucleotide substitutions that
encode the variants p.E545V, p.E545, p.E543K,
p.E559V, p.P571H, p.R573L, p.G574F, and p.T557K or
frameshift mutations that result in peptides containing1
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genic frameshift variants encode p.G538Efs*30,
p.F540Lfs*28, p.F540Sfs*27, p.V541Afs*27, p.E543Efs*25,
and p.T544T*fs24. Three nonamyloidogenic ﬁbrinogen
Aa-chain variants also have been described: p.G538R,
p.G538E, and p.R573H.15 By far the most frequently
identiﬁed amyloidogenic variant worldwide is
p.E545V.13 Studies on ex vivo amyloid deposits from pa-
tients with AFib amyloidosis have shown that the amy-
loid ﬁbril protein is associated with the C-terminus of
ﬁbrinogen Aa-chain and that only variant ﬁbrinogen
Aa chain and not wild-type ﬁbrinogen Aa chain is incor-
porated into the amyloid.4 Indeed, AFib amyloidosis has
never been reported in the absence of an FGA mutation.
Immunohistochemistry (IHC) is commonly used for the
identiﬁcation of amyloid type; however, it fails to unam-
biguously determine the amyloid type in up to 30% of
cases of systemic amyloidosis because of a combination of
high background staining, lack of epitope speciﬁcity, and/
or epitope masking.17,18 Although AFib amyloid has a
characteristic morphologic appearance on renal histology
with isolated and often extensive glomerular inﬁltration,
up to 10% of cases fail to stain immunohistochemically
with antibodies against AFib.13 Further, a similar structure
occasionally can occur in light chain amyloidosis. There-
fore, a proportion of cases of AFib amyloidosis currently
are diagnosed on the basis of amyloid with typical renal
morphology in the absence of speciﬁc IHC staining, in
conjunction with the presence of a pathogenic FGA mu-
tation on direct DNA sequencing, with the diagnosis
sometimes further supported by a family history of the
disease and/or a typical disease course.13 More recently,
proteomic analysis of amyloidotic tissue, a technique
pioneered by the Mayo Clinic,19–23 is now used in certain
specialist amyloidosis centers to identify the amyloid ﬁbril
protein, complementing the diagnostic value of histology,
IHC, and related techniques.24–27
We previously reported the identiﬁcation of several
novel variants of the AFib protein that are associated
with renal amyloidosis.13,28 Identiﬁcation initially was
made using gene analysis, with conﬁrmation by
immunohistochemistry and/or proteomics. Here, we
sought to determine whether AFib amyloidosis could
be diagnosed reliably by proteomic analysis using a
simple algorithm to identify the speciﬁc variant amy-
loidogenic peptide and whether the issue of false pos-
itives through blood contamination of amyloid tissue
can be avoided.METHODS
Patients’ Samples
This report covers patient data on 1001 Congo red–
positive clinical samples obtained either as part of2standard clinical practice at the National Amyloidosis
Centre or received from other hospitals requesting
immunohistochemical and proteomics examination.
Since early 2016, all clinical, biochemical, and prote-
omics data have been included within a single database
at our center. A further 52 samples of pre-2016 patients
with AFib were manually added to the database to
increase the proportion of AFib cases in the current
sample set. All samples had been identiﬁed as AFib
amyloid at our weekly clinical proteomic meeting based
on glomerular morphology and genetic and proteomics
analysis. To obtain proteomics control data from ﬁbrin,
a sample of whole blood was collected from a healthy
volunteer and was allowed to clot naturally. A small
portion of the clot was formalin-ﬁxed, embedded in
parafﬁn, and treated as a normal sample.
All patients were managed in accordance with the
Declaration of Helsinki, and informed consent for use
of material and publication of data was obtained. The
study was approved by the Royal Free Hospital Ethics
Committee.
Sample Collection and Digestion
Sections were cut from a single sample block for Congo red
and IHC staining as previously reported.17,26 Amyloid was
identiﬁed by presence of apple green birefringence
when viewed under crossed polarized light. Congo red–
positive material (a 6-mm section) was microdissected
using a Leica LMD7 laser capture microscope (Leica
Microsystems, Wetzlar, Germany) and collected into
0.5-ml microcentrifuge tubes (Eppendorf, Stevenage, UK)
containing 35-ml tris(hydroxymethyl)-aminomethane/
ethylenediamine tetraacetic acid/0.002% Zwittergent
buffer (Sigma-Aldrich, St. Louis, MO). Samples were
heated at 98 C for 90 minutes with occasional vortexing.
Following 60 minutes of sonication in a water bath, sam-
ples were digested with 30-ng trypsin (Promega Corpo-
ration, Madison, WI) overnight followed by treatment
with dithiothreitol (50 mg) at 99 C for 5 minutes. Water
was removed under vacuum and the samples were redis-
solved in 0.1% aqueous triﬂuoroacetic acid (Fisher Sci-
entiﬁc, Loughborough, UK) for proteomics analysis.27,29,30
Protein Identiﬁcation
Proteomics analysis was undertaken on either a Thermo
Scientiﬁc Orbitrap Velos hybrid Ion Trap-Orbitrap
Mass Spectrometer (Thermo Fisher Scientiﬁc GmbH,
Bremen, Germany) coupled to a Waters nanoAcquity
UPLC system (Waters Corp., Milford, MA)29 or, more
recently, on a Thermo Scientiﬁc Q-Exactive Plus in-
strument connected to an Ultimate 3000 nanoLC system
using a Thermo Easy-spray Acclaim PepMap column
(75 mm  15 cm, 3 mm/100 Å packing). Elution was
undertaken at 300 nl/min with a 30-min linear gradientKidney International Reports (2019) -, -–-
GW Taylor et al.: Proteomics and Fibrinogen Aa Amyloidosis CLINICAL RESEARCHof acetonitrile:water:formic acid (5:95:0.1–60:40:0.1 v/
v/v). Optima LCMS-grade water, formic acid, and tri-
ﬂuoroacetic acid were obtained from Fisher Scientiﬁc,
UK. Chromasolv LC-MS acetonitrile was obtained from
Honeywell Research Chemicals, Riedel-de Haën, Ger-
many. The new instrument was validated against a
panel of clinical samples. Raw mass spectra data ﬁles
initially were queried by Mascot (Matrix Science,
London, UK) using the Swiss-Prot human protein
database. Amyloid was identiﬁed by the presence of 2
or more of the signature proteins22 proteins: apolipo-
protein E, apolipoprotein A-IV, and serum amyloid P
component. Following the initial database search, a
modiﬁed database containing 13 known amyloidogenic
variant ﬁbrinogen Aa chain peptide sequences was
appended to Swiss-Prot and the data were reanalyzed
via this new database. The additional database
included the most common amyloidogenic variant,
p.E545V, together with the other known amyloido-
genic variants—p.E543K, p.E545K, p.T557K, p.E559V,
p.P571H, p.R573L, p.G574F, p.G538Efs*30, and
p.F540Lfs*28—and the nonamyloidogenic variants
p.G538R, p.G538E, and p.R573H. A generic 3nþ1
nucleotide deletion frameshift protein p.36-527 con-
taining the C-terminal peptide VLITLG also was
included in the database. Data were interpreted by a
panel of operators with extensive experience in amy-
loid proteomics, initially in the absence of clinical de-
tails. The presence of amyloid is accepted for Congo
red–positive material when 2 out of 3 signature pro-
teins (ApoE, ApoA4, or serum amyloid P component)
are present, each with a minimum Mascot score of 20
and 1 unique signiﬁcant peptide (in cases where Congo
red staining is equivocal or absent, the threshold is
increased to a minimum Mascot score of 50 and 1
unique signiﬁcant peptide). The minimum score for all
other proteins is set at 80 with 2 unique peptides. The
top scoring amyloidogenic protein normally is used to
type the tissue, except when ApoA1 or ApoA4 may be
implicated or when more than one potential amyloi-
dogenic protein has been identiﬁed with a similar
score. In these cases, a more detailed examination of the
tissue type, clinical presentation, and biochemistry is
required. When there are fewer than 5 proteins in total
(excluding keratins and hemoglobin), the sample may
be declared inadequate.
Polymerase Chain Reaction and Direct
Sequencing of FGA
Genomic DNA was extracted from whole blood treated
with ethylenediamine tetraacetic acid, as previously
described.31 A 707 base pair fragment of exon 5 of FGA
was ampliﬁed by polymerase chain reaction assay and
analyzed by automated sequencing. Polymerase chainKidney International Reports (2019) -, -–-reaction was carried out with Ready To Go tubes
(Amersham Pharmacia Biotech, Amersham, Buck-
inghamshire, UK) using the solutions and cycling
conditions previously described. Polymerase chain re-
action products were puriﬁed with a QIAquick poly-
merase chain reaction puriﬁcation kit (Qiagen, Hilden,
Germany) and sequenced with the Big Dye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA) according to the kit manufacturer’s protocols.
The FGA gene sequence was analyzed on the Applied
Biosystems 3130xl Genetic Analyzer using Applied
Biosystems Sequencing Analysis Software version
5.4.24.28RESULTS
The current study was undertaken to evaluate a pro-
teomics algorithm designed to identify AFib as the
amyloid type in the presence of blood contamination.
The data were extracted from the National Amyloidosis
Centre database, which since 2016 has been integrated
with our proteomics database. Proteomics data were
analyzed using the Mascot search engine (www.
matrixscience.com) to interrogate the human Swiss-
Prot database. Mascot, together with other commonly
used proteomics engines, uses a probability-based al-
gorithm to generate an identity score for each protein
based on the quality and abundance of individual
peptide mass spectra. A protein’s Mascot score is
derived from the number of total, unique, and signif-
icant peptides identiﬁed by the program; similar data,
but lacking an overall protein summary score, often are
reported using Scaffold software (Proteome Software,
Portland, OR).20,32 A full proteomics dataset is available
in Supplementary Table S1.
The proportion of patients with AFib amyloidosis
among those referred to the UK National Amyloidosis
Centre with renal amyloidosis is w5%. To ensure
development and testing of a robust diagnostic algo-
rithm, the number of AFib amyloid samples (as well as
other rare renal amyloid types with glomerular
involvement, such as ALECT2 amyloid) was manually
increased by incorporation into the new database of
proteomics data from patients with AFib amyloidosis
collected prior to 2016. After excluding duplicate and
control samples, we examined 1001 Congo red–positive
samples, of which 240 were renal and 761 were from
other tissues; amyloid signature proteins were identiﬁed
in 198 and 632 samples, respectively (Table 1). Because
AFib amyloidosis is predominantly a renal disease, we
used the identiﬁcation of renal FibA as a preliminary
diagnostic indicator when developing the algorithm.
AFib was identiﬁed by the Mascot search engine in
391 samples (of which 35% were renal). The frequency3
Table 1. Sample selection based on the criteria adopted for the
identiﬁcation of ﬁbrinogen Aa as the amyloid protein
Samples Renal Nonrenal Total
All (Congo red–positive) 240 761 1001
Amyloid signature (at least 2/3 of ApoA-IV, ApoE,
and SAP)
198 632 830
FibA identiﬁed 137 254 391
FibA score >80, 2 99 95 194
FibA score > (Bb þ g) 84 30 114
FibA top score 68 10 78
FibA top score þ FibA > (Bb þ g) 68 6 74
FibA top score þ FibA > (Bb þ g) þ amyloid
signature
67 4 71
FibA top score þ FibA > (Bb þ g) þ amyloid
signature þ variant
64 1 65
Variant present 68 1a 69
Likely AFib by proteomics: variant present but not
either amyloid signature, top score, or FibA >
(Bb þ g)
4 0 3
IHC ﬁbrinogen 44b 1a 45
AFib clinical diagnosisc 68 0 68
AFib, ﬁbrinogen Aa-chain amyloid; ApoA-IV, apolipoprotein A-IV; ApoE, apolipoprotein
E; FibA, ﬁbrinogen Aa; IHC, immunohistochemistry; SAP, serum amyloid P.
aSoft tissue biopsy from patient with renal AFib amyloid (included in renal column).
bIncludes all FibA proteomics-positive samples plus 8 labeled no-immunospecific
staining; 16 samples were not analyzed because of insufficient material.
cSee Table 2 for clinical details.
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samples is shown in Figure 1. Clearly, the presence of
FibA alone is insufﬁcient to determine FibA as the
amyloid type. To reduce potential false identiﬁcations
based on low scoring peptides, we set a minimum
requirement for the Mascot score at $80 and at least 2Figure 1. Frequency histogram showing the distribution of Mascot
scores of signiﬁcant protein identiﬁcations of ﬁbrinogen Aa (FibA)
in all samples (blue open bars, n ¼ 391) and renal samples (red
solid bars, n ¼ 137). By requiring both a minimum acceptable
score and FibA to be the top scoring amyloid protein, the number
of FibA-positive samples is reduced to 78 (87% renal) and are
associated with renal (red solid bars, inset) rather than nonrenal
(blue solid bars, inset) samples.
4unique signiﬁcant peptides, which excluded low-
scoring proteins (n ¼ 197) and reduced the positive
FibA samples to 194 (w50% were renal). This number
was further reduced to 78 samples (87% renal) as a
result of the requirement for FibA to be the top-scoring
amyloid ﬁbril protein. The modiﬁed frequency distri-
bution for top scoring FibA is shown in Figure 1 (inset)
and demonstrates that higher scoring FibA is derived
from renal rather than nonrenal samples.
The presence of blood in the tissues may result in a
false-positive result, and thus the identiﬁcation of
FibA in amyloid tissues, even as the top-scoring
protein, is on its own insufﬁcient to make a diag-
nosis of AFib amyloidosis. In the current study, 85%
of the samples contained hemoglobin A or B chains,
with ﬁbrinogen Bb and g chains present inw20% of
all samples (Figure 2). Using hemoglobin as a marker
of blood contamination and comparing scores against
those of ﬁbrinogen Aa, Bb, and g chains showed a
qualitative difference between FibA and the other
ﬁbrinogen chains, which indicated that ﬁbrinogen
Bb and g chains were more dominant in samples
contaminated by blood. To investigate whether AFib
peptides could arise from the presence of blood
within the tissue sample, a piece of normal clotted
blood was formalin-ﬁxed, embedded in parafﬁn, and
then digested and analyzed in the same way as
clinical tissues. Hemoglobin A and B chains were
present with very high Mascot scores (7384 and
10,776, respectively). Wild-type ﬁbrinogen A aFigure 2. The Mascot scores for ﬁbrinogen Aa (a, red circles), Bb
(b, blue triangles), and g (c, green triangles) chains plotted
against the summed score for hemoglobins A and B (HbA and
HbB) chains. There is a qualitative difference between FibA and
the other groups.
Kidney International Reports (2019) -, -–-
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scores for ﬁbrinogen Bb and g chains (640 and 490,
respectively). Although probability scores are not
quantitative, these data are consistent with the
presence of similar amounts of the 3 ﬁbrinogen
chains in blood, as expected. This enabled us to
modify our algorithm to include the requirement that
the score of FibA be greater than the sum of scores of
ﬁbrinogens Bb and g (Figure 3). After further
selecting for the samples in which FibA was the top-
scoring amyloid protein, we were left with 71 sam-
ples (67 renal) that fulﬁlled the following re-
quirements: FibA as the top-scoring amyloid ﬁbril
protein plus the score FibA > (Bb þ g).
Interrogation of each of the 194 samples that were
identiﬁed by a FibA Mascot score $80 and 2 unique
signiﬁcant FibA peptides, using a modiﬁed Swiss-
Prot database containing the ﬁbrinogen A a-chain
variant peptide sequences, revealed the presence of a
known pathogenic variant AFib peptide in 68 renal
samples and 1 nonrenal (soft tissue) sample. All were
associated with FibA as a top-scoring protein and the
score of FibA > (Bb þ g). The variant was p.E545V in
63 cases and p.E543K, p.E545K, p.P571H, p.571K,
p.G538Efs*30, and p.F540Lfs*28 in 1 case each.
Sequencing of exon 5 of the FGA gene was under-
taken in all cases and conﬁrmed the proteomics
identiﬁcation of the variant ﬁbrinogen. The singleFigure 3. Comparison of individual ﬁbrinogen Aa (FibA) Mascot
scores with the sum of scores for ﬁbrinogen (Fib)Bb and g chains
in all 1001 Congo red–positive samples. Top scoring FibA
(superimposed red open circles) is associated with samples
where the score of FibA is greater than Fib(Bb þ g). The line of
equivalence for FibA/Fib(b þ g) scores is shown, together with an
expanded scale ﬁgure (inset).
Kidney International Reports (2019) -, -–-example of variant FibA detected in a nonrenal
sample was from a soft tissue biopsy taken from a
patient with AFib amyloidosis and where p.E545V
FibA also had been identiﬁed by proteomics in renal
tissue. No proteomics evidence for variant ﬁbrino-
gens was observed in any of the other samples.
Further, no FGA mutations were identiﬁed in those
for which only wild-type ﬁbrinogen had been iden-
tiﬁed in their microdissected glomerular sample.
There were 3 samples in which 2 peptide variants,
together with wild-type FibA, were identiﬁed by
proteomics, although FGA sequencing indicated that
only 1 variant was present. The quality of the raw
mass spectra eliminated the possibility of misidenti-
ﬁcation of these apparent variant peptides. They
were observed only when variant lysine was
included at positions p.573 or p.575 in the database,
generating a new in silico tryptic site. The peptides
were C-terminal to the lysine and did not contain the
variant residue, suggesting that they were indeed
present, perhaps derived from wild-type FibA by
postdeposition truncation, but were misidentiﬁed as
tryptic peptides by the variant database search. We
observed that coverage of the amyloidogenic FibA C-
terminal fragment appeared to be substantially
different between the 68 renal samples with AFib
amyloid and all other FibA-positive samples. This is
clearly shown in Figure 4, where the summed
coverage at each residue is shown for the AFib am-
yloid samples compared with all other samples con-
taining FibA. Because of the difference between
groups at p.449, this was selected as the differentia-
tion point between AFib samples. The median
(interquartile range) percentage coverage of p.449-
621 was for AFib amyloid and other samples,
respectively (Figure 4); coverage of the remaining
protein (p.20-448) was similar for both AFib and
other groups at 5.7% (3.3–8.5) and 7.7% (4.3–10.5).
Increased coverage of the p.449-621 region is a
further indicator for the deposition of FibA in amy-
loid deposits. Although the difference in coverage is
qualitatively observable, it was not considered suit-
able for quantitative analysis
Based on these data, we set the following criteria,
all of which should be met, for the identiﬁcation of
AFib amyloid by proteomics: (i) amyloid on Congo
red staining; (ii) presence of an amyloid signature
($2 of 3 amyloid signature proteins: serum amyloid
P, ApoE, or ApoA-IV); (iii) FibA identiﬁed with a
minimum Mascot score of 80 and 2 unique signiﬁcant
peptides; (iv) FibA as the top-scoring amyloid pro-
tein; (v) the score of FibA greater than the sum of
scores for ﬁbrinogen Bb þ g chains; and (vi) the
presence of a pathogenic variant. A greater sequence5
Figure 4. Protein coverage of ﬁbrinogen Aa (FibA) for all samples
with the minimum acceptable score is shown for samples from
patients diagnosed with ﬁbrinogen Aa-chain (AFib) amyloidosis (a,
n ¼ 68) and all other FibA-containing samples (b, n ¼ 126). Data
are normalized to the sample size. The median percentage
coverage and interquartile ranges are shown for residues p.20-448
and p.449-621 for AFib and other samples in (c) and (d),
respectively. These data are a guide to the difference in
coverage; however, we do not believe that these data are
amenable to statistical analysis.
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with AFib amyloid. Based on our proteomics algo-
rithm criteria, 64 renal samples and 1 nonrenal sam-
ple fulﬁlled all the criteria for AFib amyloidosis
(Table 1, Figure 5).
IHC analysis was undertaken on 845 Congo red–
positive samples, of which 45 were identiﬁed as
AFib amyloid (including the single FibA–positive soft
tissue sample). Other proteins identiﬁed included AA
(27), l (153), k (36), LECT2 (12), and TTR (136), with
no immunospeciﬁc staining mainly arising from k/l
in 415 samples. Of the 65 samples identiﬁed as AFib
amyloid by proteomics, 45 were diagnosed as AFib
amyloid by IHC, 8 were recorded as no immunospe-
ciﬁc staining, and the remainder were not analyzed
by IHC because of the lack of sufﬁcient available
tissue.
A diagnosis of AFib amyloidosis, based on clinical
presentation together with immunohistochemical,
clinical biochemistry, and genetic analysis, was made
in 68 cases (all renal, Table 2), including all of the 64
renal samples designated AFib amyloid by our algo-
rithm. The remaining 4 clinical AFib cases were all
positive for a pathogenic variant but were not diag-
nosed from the proteomics algorithm because 1 crite-
rion was not achieved. One Congo red–positive sample6was deﬁned as inadequate by proteomics but still
showed a single amyloid signature protein together
with a positive result for FibA. Another sample did not
show FibA > (Bb þ g) in the initial search, and in 2
samples either heavy chain or light chain k were the
top scoring proteins. In each case the clinical,
morphologic, and laboratory data were consistent with
AFib amyloid. Both the proteomics algorithm and
clinical and biochemical parameters excluded a AFib
amyloid in all other samples.DISCUSSION
Diagnosis of hereditary AFib amyloidosis can be chal-
lenging because pathogenic FGA mutations are associ-
ated with variable disease penetrance such that there
may be no family history of renal dysfunction in
affected individuals.13 IHC staining is not always suc-
cessful, and the characteristic AFib amyloid renal bi-
opsy morphology of isolated glomerular amyloid may
occur, albeit rarely, in other amyloidoses. Proteomic
analysis of Congo red–positive laser microdissected
tissue samples, introduced by Dogan and colleagues at
the Mayo Clinic,19–23 is now used routinely in our
center for the identiﬁcation of amyloid deposits.29,30,33
We use a single database search engine (Mascot) to
identify proteins, although we note that others conjoin
the results from multiple engines.22,34,35 Although each
of the major search engines can readily identify the
major components present in a mixture, they may
separately identify additional and different low-
abundance peptides. Although this can be of value
when analyzing large protein datasets,36 it is perhaps of
less importance for identifying a known amyloidogenic
protein as a major component in laser-captured Congo
red–positive tissue where the amyloid protein is
concentrated and background impurities are reduced.
Probability-based methods such as Mascot are not
quantitative; however, more abundant proteins are
normally associated with higher probability scores,
which can be used as surrogate markers for protein
amount.
Identiﬁcation of more than one ﬁbril protein by
proteomic analysis of micro-dissected amyloid can
result in ambiguity with respect to determining the
amyloid type.30 In the case of FibA, the protein can
arise from small insoluble thrombi sealed within
excised tissue samples that are placed directly into
formalin-saline and typically is associated with the
co-presence of ﬁbrinogen Bb and g peptides on
sample digestion. Further, extensive washing of ﬁxed
tissue before digestion often fails to eliminate
thrombus-derived ﬁbrinogen. In our sample set,
>85% of samples contained hemoglobin and 20%Kidney International Reports (2019) -, -–-
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Figure 5. The proteomics algorithm for identifying ﬁbrinogen Aa (FibA) as the amyloid protein. The algorithm is based on the Mascot score of
amyloid and signature proteins together with the number of unique signiﬁcant peptides (USPs) identiﬁed by the search engine. It is essential to
apply the results of the proteomics algorithm in conjunction with clinical and laboratory data. Apo, apolipoprotein; ID, identiﬁcation; IHC,
immunohistochemistry; min, minimum; MS, mass spectrometric analysis.
GW Taylor et al.: Proteomics and Fibrinogen Aa Amyloidosis CLINICAL RESEARCHcontained ﬁbrinogen Bb and g chains, consistent with
blood contamination. By including a requirement for
the score of FibA to be greater than the sum of scores
for ﬁbrinogens Bb and g, amyloid can be identiﬁed
even in the presence of blood contamination. A high
FibA residue coverage between p.449-621 was a
further indicator of AFib amyloid, albeit nonspeciﬁc
for the diagnosis. This is likely to reﬂect the fact that
the amyloid is believed to be composed of a cleaved
fragment of FibA containing this region.4 This
observation can be used as an additional guide to the
possible presence of AFib amyloid.Kidney International Reports (2019) -, -–-The identiﬁcation of a pathogenic variant by prote-
omics was central to the development of our diagnostic
algorithm. Because wild-type AFib is not known to be
amyloidogenic, the presence of a known amyloidogenic
variant ﬁbrinogen peptide or the generic frameshift
protein containing the C-terminal peptide VLITLG in
the specimen is diagnostic of AFib amyloidosis. Prote-
omics is sample type independent and, in principle, is
ideally suited to variant analysis. In this study the
variant in all 68 renal samples from AFib patients were
identiﬁed, with ﬁndings corroborated in each case by
DNA sequencing. The likely presence of truncated7
Table 2. Summary of demographic or clinical characteristics of
patients with ﬁbrinogen Aa-chain amyloidosis
AFib amyloid diagnoses
Total 68
Male 41
Female 27
Age at diagnosis, yr, median (range) 60 (7–84)
Congo red–positive, n 68
Immunohistochemistry
Fibrinogen Aa–positive 44
No immunospeciﬁc staining 8
Not done 16
Kidney amyloid by SAP scintigraphy at diagnosis
Yes 52
Not done 16
Supine systolic blood pressure at diagnosis, mm Hg, median
(range)
147 (119–179)
Standing systolic blood pressure at diagnosis, mm Hg, median
(range)
148 (117–191)
Serum creatinine at diagnosis, mmol/L, median (range) 226 (73–761)
Serum albumin at diagnosis, g/L, median (range) 31 (14–48)
24-h urinary protein loss at diagnosis, g, median (range) 6.2 (0.1–29.7)
eGFR at diagnosis, ml/min per 1.73 m2, median (range) 22.5 (15–83)
Median time from diagnosis to ESRD by KM, mo, median 24
Time from diagnosis to dialysis among patients who reached
ESRD, mo
n 40
Median 15.4
Range –160.4a–87.6
Time from diagnosis to kidney transplantation among patients
who received a kidney transplant, mo
n 17
Median 30.9
Range –65.5b–112.7
AFib, ﬁbrinogen Aa-chain; eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage
renal disease; KM, Kaplan-Meier analysis; SAP, serum amyloid P.
aCommenced dialysis prior to diagnosis.
bReceived kidney transplant prior to diagnosis.
No immunospecific staining is nondiagnostic of amyloid type.
CLINICAL RESEARCH GW Taylor et al.: Proteomics and Fibrinogen Aa AmyloidosisFibA in some amyloid deposits explains the apparent
identiﬁcation of 2 separate variants in a some samples,
which demonstrates the importance of discernment in
the interpretation of search results, particularly when
using modiﬁed or extended databases. The variant
peptide approach of proteomics will not identify novel,
previously unreported variants or those that form
tryptic peptides, which are too small or large to
generate good-quality spectra—hence the utility of the
other proteomic data in generating a high index of
suspicion of AFib amyloidosis that should prompt ge-
netic testing.
The algorithm for proteomics diagnosis of AFib
amyloid (Figure 5) is designed as a guide to diagnosis
and should be used in conjunction with clinical and
biochemical data. The model in our specialist center is
to interpret proteomics data in the context of a weekly
multidisciplinary meeting. We have set thresholds for
FibA and other protein scores based on our extensive
proteomics dataset coupled with our clinical and8biochemical experience. Each sample in our database is
individually reviewed by a team consisting of a senior
clinician together with members of the biochemistry
and proteomics groups. Sixty-eight patients from this
data group were diagnosed with renal AFib amyloid-
osis. The algorithm was in agreement in 64 of 68 of
these cases. Each of the remaining 4 patients with AFib
was not diagnosed on the basis of the proteomics al-
gorithm because of the failure of a single criterion, but
each had a FibA variant, identiﬁed by both proteomics
and genetic sequencing, and a characteristic clinical
picture.
In conclusion, the diagnosis of AFib amyloidosis
may be diagnosed conﬁdently on the basis of the pro-
teomics algorithm reported here, which takes into ac-
count the probability-based identity score of FibA
compared with that of other potential amyloid proteins,
the score relationship between the ﬁbrinogens Aa, Bb,
and g chains, coverage of the p.449-621 region, and the
presence of an amyloidogenic FibA variant. A general
amyloidosis diagnostic algorithm has been reported
recently.37 Although algorithms offer an objective
approach to amyloid identiﬁcation, we are of the ﬁrm
opinion that proteomics results always should be
examined in conjunction with clinical details together
with the results of immunohistochemistry, genetic re-
sults, and clinical biochemistry.DISCLOSURE
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